NCT01016093

Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients

Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients: A Prospective Pilot Study

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Tehran University of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is prospective randomized, double blind study designed to evaluate the use of zoledronic acid in the prevention prevention of bone loss post allogenic BMT done for beta-thalassemia major patients.

Conditions

• Beta-Thalassemia
• Bone Marrow Transplantation

Interventions

Type	Name	Description
DRUG	Zoledronic acid	Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
DRUG	Placebo	Placebo

Timeline

• Start date: 2009-11-01
• Primary completion: 2011-11-01
• Completion: 2011-12-01
• First posted: 2009-11-18
• Last updated: 2011-07-26

Locations

1 site across 1 country: Iran